Benefit-Risk Assessment of Drotrecogin Alfa (Activated) in the Treatment of Sepsis

ISSN： 0114-5916

Source： Drug Safety, Vol.30, Iss.11, 2007-01, pp. : 995-1010

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis

By McCoy Christopher

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 625-637

Informa Healthcare

Access to resources Recommend Favorite

Drotrecogin Alfa (Activated): A Pharmacoeconomic Review of its Use in Severe Sepsis

By Frampton J.E. Foster R.H.

PharmacoEconomics, Vol. 22, Iss. 7, 2004-01 ,pp. : 445-476

Adis International

Access to resources Recommend Favorite

Drotrecogin Alfa (Activated)

By Lyseng-Williamson K.A. Perry C.M.

Drugs, Vol. 62, Iss. 4, 2002-04 ,pp. : 617-630

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer

By Dienstmann Rodrigo

Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. : 15-25

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Levetiracetam in the Treatment of Partial Seizures

By Abou-Khalil Bassel

Drug Safety, Vol. 28, Iss. 10, 2005-01 ,pp. : 871-890

Adis International

Access to resources Recommend Favorite